Last reviewed · How we verify
Tedizolid IV
Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).
At a glance
| Generic name | Tedizolid IV |
|---|---|
| Also known as | Sivextro, TR-701 FA, MK-1986 |
| Sponsor | University of Southern California |
| Drug class | Oxazolidinone antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tedizolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits the initiation of protein synthesis. This mechanism is bacteriostatic, halting bacterial growth and allowing the immune system to clear the infection. Tedizolid is a prodrug that is converted to its active form in vivo and has enhanced potency and pharmacokinetics compared to linezolid, its predecessor.
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI)
- Community-acquired bacterial pneumonia (CABP)
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
- Peripheral neuropathy
- Optic neuropathy
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (PHASE3)
- A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014) (PHASE1)
- Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis (PHASE4)
- Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers (PHASE1)
- A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) (PHASE1)
- Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) (PHASE3)
- Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tedizolid IV CI brief — competitive landscape report
- Tedizolid IV updates RSS · CI watch RSS
- University of Southern California portfolio CI